Profusa Partners with Angiopro to Enhance Oxygen Monitoring in Europe
Expanding Horizons with New Partnerships
Profusa, a leading digital health company based in Berkeley, California, is making significant strides in the European market with its recent collaboration with Angiopro GmbH. This new partnership aims to enhance the distribution of its Lumee Oxygen platform, designed for continuous monitoring of individual biochemistry. Targeted regions include prominent areas like Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia.
Increased Market Coverage
The agreement with Angiopro is a pivotal move for Profusa, expanding its coverage to reach approximately 35% of the European Union's population. This expansion aligns with the critical need for innovative health technologies, especially considering the 300,000 annual endovascular procedures performed in these regions.
Strength of Partnership
"We see great potential in Profusa's Lumee platform technology," expressed Benjamin J. Rieck, the CEO of Angiopro. By using their established networks and regulatory expertise, Angiopro aims to facilitate the successful market entry of Lumee, which promises to enhance patient outcomes in vascular and peripheral diseases and offers capabilities for monitoring chronic conditions like diabetes.
About Angiopro
Angiopro specializes in bringing innovative cardiovascular technologies to market. Their infrastructure is built on a foundation of high-quality interventional cardiology and vascular surgery tools, coupled with a strong understanding of healthcare IT. This experience is invaluable as they seek to push Profusa's technologies into the hands of professionals who can leverage them for improved patient care.
Profusa's Vision for the Future
With their innovative Lumee technology, Profusa is positioned to tap into a potential global market exceeding $10.5 billion. Their approach not only aims to address immediate healthcare needs, such as peripheral artery disease and chronic wounds but also strives to provide a real-time healthcare experience that significantly improves patient engagement and outcomes.
Innovative Health Technologies
Ben Hwang, Ph.D., the company’s Chairman and CEO, emphasized the importance of this partnership: "With Angiopro, we can build a robust distribution network that will facilitate the introduction of our real-time personal healthcare technologies to the clinical community." This collaboration signals an exciting phase in Profusa's journey toward addressing significant market demands.
Commitment to Patient Care
Profusa is not just focusing on expansion; it's committed to revolutionizing how healthcare operates by providing long-lasting and affordable biosensors. Their mission revolves around creating products that deliver actionable, medical-grade data which clinicians can rely upon for accurate diagnostics.
Conclusion
The partnership between Profusa and Angiopro heralds a new chapter in the provision of innovative healthcare solutions across Europe. As they work together to bring Lumee technology to market, both companies are dedicated to enhancing patient care and making a significant impact in the healthcare landscape.
Frequently Asked Questions
What is the Lumee Oxygen platform?
The Lumee Oxygen platform is an advanced technology designed for continuous monitoring of individual biochemistry, particularly useful in managing vascular health.
What regions will Profusa target with this new partnership?
Profusa plans to target Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia as initial markets for the Lumee platform.
What are the benefits of using the Lumee technology?
Benefits include enhanced patient monitoring, real-time data collection, and improved management of chronic diseases like diabetes and peripheral artery disease.
Why is the partnership with Angiopro significant?
Angiopro's expertise and established networks in the MedTech field will help accelerate the market entry and success of Profusa's technologies in Europe.
How does Profusa plan to improve patient care?
By providing innovative biosensors and real-time data solutions, Profusa aims to offer personalized healthcare that clinicians can trust, ultimately enhancing patient outcomes.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.